BRCA2 and ovarian carcinoma: Although differences in response to Olaparib are cell line-dependent, PEO1 cells harbor a nonsense mutation in exon 11 of BRCA2 [31]; this genomic feature has been shown to render ovarian cancer patients more sensitive to Olaparib treatment [32].